Menopausal hormone therapy, migraine history, and headache severity: Results from the Women's Health Initiative Hormone Therapy clinical trials
Headache: The Journal of Head and Face Pain · 2026
DOI: 10.1111/head.70168 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Headache: The Journal of Head and Face Pain, 2026. Verfasst von Holly M Crowe und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Women's Health, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Estrogen Replacement Therapy, Headache. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIA NIH HHS, WHI NIH HHS.
Abstract (Originalsprache)
Objective
The aim of this study was to evaluate the association of oral menopausal hormone therapy (estrogen only [E‐only] or estrogen and progestin [E+P]), as compared to placebo on postmenopausal headache severity among females with and without a history of migraine in the Women's Health Initiative Hormone Therapy (WHI‐HT) trials.
Background
Migraine is three times more common among females than males and is a major source of pain and disability among women throughout the life course. Previous observational research found a positive association between menopausal hormone therapy (MHT) use and migraine prevalence, but the longitudinal association of MHT with postmenopausal migraine severity is unclear.
Methods
We examined changes in self‐reported headache severity between baseline and year 1 in 22,876 females (average age 64 years) across the United States enrolled in the WHI‐HT trials between 1993 and 1998. We conducted a secondary, stratified analysis of data of two parallel, randomized, placebo‐controlled clinical trials to estimate the association of MHT and headache severity overall and stratified by history of migraine at baseline. Additionally, we assessed the association between MHT and headache trajectory, based on whether headaches worsened over the follow‐up period.
Results
At baseline, the prevalence of a lifetime migraine diagnosis was 10%. Among participants with a history of migraine, randomization to E‐only MHT was not associated with more severe headache at 1 year (adjusted odds ratio [aOR] = 1.14, 95% confidence interval [CI]: 0.90–1.44), or worsening headache trajectory (adjusted risk ratio [aRR] = 0.98, 95% CI: 0.71–1.34) after 1 year. Randomization to E+P MHT was modestly associated with more severe headache, although estimates did not reach statistical significance (aOR = 1.21, 95% CI: 0.98–1.50). E+P MHT was significantly associated with worsening headache trajectory (aRR= 1.53, 95% CI: 1.14–2.03). Among those without a migraine history, E‐only MHT was not strongly associated with moderate‐to‐severe headache severity (aOR: 1.11, 95% CI: 1.01–1.21) or worsening headache trajectory (aRR = 1.08 95% CI: 0.96–1.22) after 1 year. However, E+P MHT was associated with modestly increased odds of moderate‐to‐severe headache severity (aOR = 1.14, 95% CI: 1.06–1.23) and a higher likelihood of worsening headache trajectory (aRR = 1.18, 95% CI: 1.07–1.30) after 1 year.
Conclusions
In this study of MHT in the WHI hormone therapy trial participants, E‐only MHT was not associated with increased odds of more severe postmenopausal headache severity. Among those with a history of migraine, E+P MHT was associated with more severe and worsening postmenopausal headache. Further research on the effect of newer MHT formulations on postmenopausal headache is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Women's Health, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Harvard Medical School, Boston, Massachusetts, USA.
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
- Department of Emergency Medicine, Robert Larner, MD College of Medicine, University of Vermont, Burlington, Vermont, USA.
- Herbert Wertheim School of Public Health and Human Longevity Science and Division of Geriatrics, Gerontology, and Palliative Care, Department of Medicine, University of California San Diego, La Jolla, California, USA.
- Department of Epidemiology and Biostatistics, Drexel University, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Holly M Crowe
Förderung
- NHLBI NIH HHS
- NIA NIH HHS
- WHI NIH HHS
- NIH HHS
- NIMH NIH HHS
- National Institutes of Health
Zitieren
APA
Crowe, H. M., Madsen, T. E., Rich-Edwards, J. W., Shadyab, A. H., Liu, L., Farland, L. V., Schnatz, P. F., Manson, J. E., Rexrode, K. M., & Stefanick, M. L. (2026). Menopausal hormone therapy, migraine history, and headache severity: Results from the Women's Health Initiative Hormone Therapy clinical trials. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.70168
Vancouver
Crowe HM, Madsen TE, Rich-Edwards JW, Shadyab AH, Liu L, Farland LV, et al. Menopausal hormone therapy, migraine history, and headache severity: Results from the Women's Health Initiative Hormone Therapy clinical trials. Headache: The Journal of Head and Face Pain. 2026. doi:10.1111/head.70168
BibTeX
@article{Crowe2026,
author = {Crowe, Holly M and Madsen, Tracy E and Rich-Edwards, Janet W and Shadyab, Aladdin H and Liu, Longjian and Farland, Leslie V and Schnatz, Peter F and Manson, JoAnn E and Rexrode, Kathryn M and Stefanick, Marcia L},
title = {Menopausal hormone therapy, migraine history, and headache severity: Results from the Women's Health Initiative Hormone Therapy clinical trials},
journal = {Headache: The Journal of Head and Face Pain},
year = {2026},
doi = {10.1111/head.70168}
}
EUVIMED